New Self-Administered Inhaled Gene Therapy Linked to Mesothelioma Survival
| | |

New Self-Administered Inhaled Gene Therapy Linked to Mesothelioma Survival

A team of doctors in Japan have developed a new oral inhaled gene therapy for the treatment of mesothelioma. This is a new gene therapy that mesothelioma patients can self-administer, much like an asthma inhaler. There’s new evidence that therapies that prevent cancer cells from forming new blood vessels may offer a better way to approach malignant pleural mesothelioma. Gene therapy has attracted attention in recent years. A new study suggests that inhalable gene drugs are effective treatments for asbestos-induced malignant pleural mesothelioma. Gene Therapy Treatments Mesothelioma is the most deadly of several diseases caused by asbestos exposure, including lung cancer and asbestosis. Most people who develop mesothelioma live less than a year after diagnosis. It is most common in…

COPD Drug Might Help with Drooling in Pleural Mesothelioma Patients
| | | |

COPD Drug Might Help with Drooling in Pleural Mesothelioma Patients

A UK doctor says a drug used to treat COPD can help with drooling in pleural mesothelioma patients on palliative care.  Dr. Claire Plunkett recently published the case report of a mesothelioma patient receiving palliative care. The patient developed a problem with drooling and swallowing. The medical term for drooling is sialorrhoea. It can happen in people with certain conditions or on certain drugs. Doctors at Farleigh Hospice in Chelmsford, UK treated the man with a glycopyrronium bromide inhaler. Glycopyrronium is normally used for patients with chronic obstructive pulmonary disorder (COPD).  The treatment cured the problem in just a few days. Plunkett says this is evidence that glycopyrronium is a good option to treat drooling in pleural mesothelioma patients. What…